William Blair Analysts Lower Earnings Estimates for VKTX

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Research analysts at William Blair reduced their Q2 2025 earnings per share (EPS) estimates for Viking Therapeutics in a report released on Wednesday, April 23rd. William Blair analyst A. Hsieh now forecasts that the biotechnology company will post earnings per share of ($0.45) for the quarter, down from their prior estimate of ($0.36). The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.56) per share. William Blair also issued estimates for Viking Therapeutics’ Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.87) EPS, Q1 2026 earnings at ($0.54) EPS, Q2 2026 earnings at ($0.55) EPS, Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.57) EPS, FY2026 earnings at ($2.22) EPS and FY2027 earnings at ($2.79) EPS.

A number of other equities research analysts also recently weighed in on the company. The Goldman Sachs Group assumed coverage on Viking Therapeutics in a research report on Tuesday, April 8th. They set a “neutral” rating and a $30.00 price target on the stock. Citigroup assumed coverage on Viking Therapeutics in a research note on Friday, February 7th. They set a “neutral” rating and a $38.00 price objective on the stock. B. Riley reaffirmed a “buy” rating and set a $96.00 price objective (down from $109.00) on shares of Viking Therapeutics in a research note on Friday, February 7th. Morgan Stanley reduced their price objective on Viking Therapeutics from $105.00 to $102.00 and set an “overweight” rating on the stock in a research note on Thursday, April 24th. Finally, Maxim Group reduced their price objective on Viking Therapeutics from $120.00 to $70.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $87.15.

Viking Therapeutics Stock Up 3.8 %

NASDAQ VKTX opened at $25.94 on Monday. The stock’s 50-day simple moving average is $26.35 and its two-hundred day simple moving average is $40.06. Viking Therapeutics has a twelve month low of $18.92 and a twelve month high of $81.86. The company has a market capitalization of $2.91 billion, a price-to-earnings ratio of -25.94 and a beta of 0.84.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings results on Wednesday, April 23rd. The biotechnology company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). During the same quarter last year, the firm posted ($0.26) earnings per share. The business’s revenue was up .0% compared to the same quarter last year.

Insider Buying and Selling at Viking Therapeutics

In other Viking Therapeutics news, Director Sarah Kathryn Rouan bought 1,240 shares of the stock in a transaction dated Monday, March 31st. The stock was purchased at an average cost of $24.15 per share, for a total transaction of $29,946.00. Following the completion of the acquisition, the director now owns 1,240 shares of the company’s stock, valued at approximately $29,946. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On Viking Therapeutics

Several large investors have recently made changes to their positions in VKTX. World Investment Advisors LLC purchased a new position in shares of Viking Therapeutics during the third quarter valued at approximately $240,000. Tidal Investments LLC lifted its holdings in shares of Viking Therapeutics by 296.8% during the third quarter. Tidal Investments LLC now owns 15,190 shares of the biotechnology company’s stock valued at $962,000 after purchasing an additional 11,362 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Viking Therapeutics by 29.9% during the third quarter. Principal Financial Group Inc. now owns 593,528 shares of the biotechnology company’s stock valued at $37,576,000 after purchasing an additional 136,729 shares during the last quarter. Eagle Bay Advisors LLC purchased a new position in Viking Therapeutics in the 4th quarter worth approximately $92,000. Finally, Salem Investment Counselors Inc. lifted its position in Viking Therapeutics by 557.8% in the 4th quarter. Salem Investment Counselors Inc. now owns 3,289 shares of the biotechnology company’s stock valued at $132,000 after acquiring an additional 2,789 shares in the last quarter. 76.03% of the stock is currently owned by hedge funds and other institutional investors.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.